With over 25 years of engineering, management, and product and business development, Awni is Rostrum’s President, CEO, Co-founder and Co-developer. He was the Principal Co-founder and Co-developer of Saturn Biomedical and the GlideScope® Video Laryngoscope (Acquired by Verathon in January 2006) and other successful ventures. Assoc. P. Eng. of BC and Ontario.
Rostrum’s Director and Business Advisor with extensive experience that spans market development and commercialization in the anesthesia and pharmaceutical markets. Will is the former CEO and owner of Vitaid Ltd. until the acquisition by the LMA Company Ltd./Teleflex in Oct.2012. He has contributed to the successful commercialization and distribution in Canada and the US for the GlideScope® Video Laryngoscope, and other medical devices in the anesthesiology and emergency medicine markets.
Rostrum’s Director and Business Advisor, Dr. Brady, is CEO of C. Brady GesMBH & Co KG in Vienna, Austria. He completed medical studies at Vienna University and qualified for government licenses. Since 1995, he has been managing the pharmaceutical and medical devices divisions of the company.
Managing Director at Yonjin Capital; Ph.D. in Molecular Genetics, Wash. Univ. (St. Louis)
Over twenty years’ experience in biotech and pharma research and development/business development. Formerly a global lead of business development/external innovation of Sanofi Neuroscience. Board member/board observer of multiple Yonjin/Yonghua North America portfolio companies.
Professor Emeritus, Department of Anesthesia, University of Toronto.
Service d’Anesthésie-Réanimation, Hôpital Européen Georges Pompidou Paris.
Department of Anesthesiology and Pain Medicine UC Davis School of Medicine, Sacramento, California
Professor and Head; Division of Cardiac – Thoracic – Vascular Anesthesia and Intensive Care. Anesthesia, Allgemeines Krankenhaus der Stadt Wien (AKH), Vienna, Austria
Dr. Matteo Parotto, MD, PhD – Staff anesthesiologist at Toronto General Hospital, clinical fellowships in critical care medicine, cardiovascular anesthesia and cardiac intensive care. His understanding of physiology and cardiorespiratory pathology will be a real asset during Rostrum’s next phase of activity.
Nathan Ayoubi – Vice President
Nathan completed his studies at the University of British Columbia with a B.Sc. and the University of Victoria in Project Management. He is the co-developer of the VQm® group of products and has been with Rostrum since its inception in 2009. Nathan is closely involved with the Medical Advisory Board and clinicians globally and focuses on the clinical validation efforts with Rostrum’s Clinical Specialists. He guides the Technical, Clinical, Regulatory Affairs, and Quality Assurance and Commercial managers in achieving company objectives.
Steven Poon, PhD – Director, Engineering
Steven has over 30 years in the life science industry with experience in managing and developing automation products and applications in biotechnology from concept to commercialization. He has a proven ability in innovation, fostering interdepartmental collaboration, and delivering success. Steven holds a Ph.D. in Electrical Engineering from the University of British Columbia and has created numerous machine vision applications.
James Garry, PhD – Director, Design and Development
James directs the development of novel devices and processes for Rostrum Medical. He has a background in Applied Aerospace Sciences and was instrumental in the design and calibration of sensors on a handful of planetary spacecraft for NASA and ESA. He is a member of two ASTM committees and has held the title of ‘Chartered Physicist’ since 2008.
Hanna McGregor, PhD – Clinical Researcher
Hanna analyzes the medical applications of Rostrum’s products, liaises with the Medical Advisory Board to determine Rostrum’s overall clinical direction, and oversees the development and evaluation of product clinical testing. Her background includes interdisciplinary lung disease research, clinical applications of novel technologies, and design of research studies for new medical devices. Hanna received her Ph.D. from the University of British Columbia by conducting pilot studies and clinical trials utilizing spectroscopic technologies to aid in the detection of early lung cancers.